Ascendis Pharma A/S vs Avient Corporation — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Avient Corporation trades at $45.51 (market cap $4.17B). The key difference: Ascendis Pharma A/S is far larger — about 4× Avient Corporation's market cap, and Avient Corporation pays a 2.42% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | AVNT | |
|---|---|---|
Market Cap | $16.67B | $4.17B |
Sector | Health | Technology |
52-Week High | $277.18 | $45.69 |
52-Week Low | $189.74 | $27.48 |
Enterprise Value | $17.04B | $5.62B |
Dividend Yield | — | 2.42% |
Trailing returns across standard periods
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →